Characteristics of the studies, pharmacokinetics and dose recommendations related to gentamicin
| Study | n | PNA | Weight | Study design | Group | Model | Modality | Administered dose | Vd | CL | t1/2 (hours) | Recommended dose |
| Dodge et al,25 USA | 11 | 37–42 PMA | 2.67–5.10 | P 1 group | Neonates and infants | 1-compartment with NPEM | VV–VA | 2.5 mg/kg loading dose and every 8–12 hours maintenance dose | From 0.748 L/kg to 0.471 L/kg after ECMO was discontinued ↑58.8% | From 0.239 L/hour to 0.350 L/hour after ECMO was discontinued ↓31.7% | From 9.24 hours to 3.87 hours after ECMO was discontinued ↑138.7% | 4.3 mg/kg loading dose 3.7 mg/kg every 18–24 hours of maintenance dose. |
| Moffett et al,22 USA | N: 28 I: 5 | 0.17 (0.12–0.82) months | 3.1 (2.4–3.8) | R 1 group | Mostly neonates and infants | 2-compartment with NONMEM | VV–VA | 1.8 mg/kg/dose | 0.60 L/kg – | 0.03 L/kg/hour – | – | Children with elevated serum creatinine values should have extended dosing intervals (4–5 mg/kg/day). |
Boldfaced fonts represent comparisons with controls within the same study. In other studies, they represent comparisons with non-ECMO neonates from a different published study.
CL, clearance; ECMO, extracorporeal membrane oxygenation; I, infants; N, neonates; NONMEM, non-linear mixed-effects modelling; NPEM, non-parametric expectation and maximisation; P, prospective; PMA, postmenstrual age; PNA, postnatal age; R, retrospective; t1/2, elimination half-life; VA, veno-arterial; Vd, volume of distribution; VV, veno-venous.